Association of Activated Clotting Time–Guided Anticoagulation with Complications during Extracorporeal Membrane Oxygenation Support: A Systematic Review and Meta-Analysis
Authors' conclusion
Even though ACT is a widely used heparin monitoring tool, the evidence on its association with hemorrhagic or thromboembolic events is still controversial and limited.
Study context
- Population
- Patients receiving extracorporeal membrane oxygenation (ECMO) support with activated clotting time (ACT)-guided anticoagulation monitoring8 studies
- Comparison
- ACT values in patients with vs without bleeding or thrombosis
- Outcome
- Average ACT values in patients with vs without bleeding
Methodological detailsScopus and PubMed searched, July 2023; 3,177 publications identified
- Scopus and PubMed searched, July 2023; 3,177 publications identified
Pooled result
As reported in the abstract
Average ACT values, patients with vs without bleeding
- No significant difference in ACT between patients with and without bleeding
- 8 studies
Further pooled results
| Outcome | SMD (95% CI) | P value | |
|---|---|---|---|
| Average ACT, thrombosis vs no thrombosis (3 studies, n = 117)I2 = 81.1% | 0.47 (−0.50 to 1.44) | P = 0.342 | |
| −1012Difference (linear scale) |
Average ACT, thrombosis vs no thrombosis (3 studies, n = 117)
- No significant differences
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association of Activated Clotting Time–Guided Anticoagulation with Complications during Extracorporeal Membrane Oxygenation Support: A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth. Published 7 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →